Copyright Reports & Markets. All rights reserved.

Global Urotropin for Injection Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Urotropin for Injection Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 75 Unit
    • 1.3.3 150 Unit
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Urotropin for Injection Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Clinic
  • 1.5 Global Urotropin for Injection Market Size & Forecast
    • 1.5.1 Global Urotropin for Injection Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Urotropin for Injection Sales Quantity (2021-2032)
    • 1.5.3 Global Urotropin for Injection Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Yantai Dongcheng North Pharmaceutical
    • 2.1.1 Yantai Dongcheng North Pharmaceutical Details
    • 2.1.2 Yantai Dongcheng North Pharmaceutical Major Business
    • 2.1.3 Yantai Dongcheng North Pharmaceutical Urotropin for Injection Product and Services
    • 2.1.4 Yantai Dongcheng North Pharmaceutical Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Yantai Dongcheng North Pharmaceutical Recent Developments/Updates
  • 2.2 Maanshan Fengyuan Pharmaceutical
    • 2.2.1 Maanshan Fengyuan Pharmaceutical Details
    • 2.2.2 Maanshan Fengyuan Pharmaceutical Major Business
    • 2.2.3 Maanshan Fengyuan Pharmaceutical Urotropin for Injection Product and Services
    • 2.2.4 Maanshan Fengyuan Pharmaceutical Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Maanshan Fengyuan Pharmaceutical Recent Developments/Updates
  • 2.3 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd.
    • 2.3.1 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Details
    • 2.3.2 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Major Business
    • 2.3.3 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Urotropin for Injection Product and Services
    • 2.3.4 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Recent Developments/Updates
  • 2.4 Ningbo Human Health Pharmaceutical Group
    • 2.4.1 Ningbo Human Health Pharmaceutical Group Details
    • 2.4.2 Ningbo Human Health Pharmaceutical Group Major Business
    • 2.4.3 Ningbo Human Health Pharmaceutical Group Urotropin for Injection Product and Services
    • 2.4.4 Ningbo Human Health Pharmaceutical Group Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Ningbo Human Health Pharmaceutical Group Recent Developments/Updates
  • 2.5 Livzon Group
    • 2.5.1 Livzon Group Details
    • 2.5.2 Livzon Group Major Business
    • 2.5.3 Livzon Group Urotropin for Injection Product and Services
    • 2.5.4 Livzon Group Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Livzon Group Recent Developments/Updates
  • 2.6 Ningbo Human Health Pharmaceutical
    • 2.6.1 Ningbo Human Health Pharmaceutical Details
    • 2.6.2 Ningbo Human Health Pharmaceutical Major Business
    • 2.6.3 Ningbo Human Health Pharmaceutical Urotropin for Injection Product and Services
    • 2.6.4 Ningbo Human Health Pharmaceutical Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Ningbo Human Health Pharmaceutical Recent Developments/Updates
  • 2.7 Qingdao Kangyuan Pharmaceutical
    • 2.7.1 Qingdao Kangyuan Pharmaceutical Details
    • 2.7.2 Qingdao Kangyuan Pharmaceutical Major Business
    • 2.7.3 Qingdao Kangyuan Pharmaceutical Urotropin for Injection Product and Services
    • 2.7.4 Qingdao Kangyuan Pharmaceutical Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Qingdao Kangyuan Pharmaceutical Recent Developments/Updates
  • 2.8 Shanghai Tianwei Biopharmaceutical Co., Ltd.
    • 2.8.1 Shanghai Tianwei Biopharmaceutical Co., Ltd. Details
    • 2.8.2 Shanghai Tianwei Biopharmaceutical Co., Ltd. Major Business
    • 2.8.3 Shanghai Tianwei Biopharmaceutical Co., Ltd. Urotropin for Injection Product and Services
    • 2.8.4 Shanghai Tianwei Biopharmaceutical Co., Ltd. Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Shanghai Tianwei Biopharmaceutical Co., Ltd. Recent Developments/Updates
  • 2.9 Ferring GmbH
    • 2.9.1 Ferring GmbH Details
    • 2.9.2 Ferring GmbH Major Business
    • 2.9.3 Ferring GmbH Urotropin for Injection Product and Services
    • 2.9.4 Ferring GmbH Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Ferring GmbH Recent Developments/Updates
  • 2.10 IBSA Group
    • 2.10.1 IBSA Group Details
    • 2.10.2 IBSA Group Major Business
    • 2.10.3 IBSA Group Urotropin for Injection Product and Services
    • 2.10.4 IBSA Group Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 IBSA Group Recent Developments/Updates
  • 2.11 Merck
    • 2.11.1 Merck Details
    • 2.11.2 Merck Major Business
    • 2.11.3 Merck Urotropin for Injection Product and Services
    • 2.11.4 Merck Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Merck Recent Developments/Updates
  • 2.12 Livzon
    • 2.12.1 Livzon Details
    • 2.12.2 Livzon Major Business
    • 2.12.3 Livzon Urotropin for Injection Product and Services
    • 2.12.4 Livzon Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Livzon Recent Developments/Updates
  • 2.13 Gedeon Richter
    • 2.13.1 Gedeon Richter Details
    • 2.13.2 Gedeon Richter Major Business
    • 2.13.3 Gedeon Richter Urotropin for Injection Product and Services
    • 2.13.4 Gedeon Richter Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Gedeon Richter Recent Developments/Updates
  • 2.14 GenSci
    • 2.14.1 GenSci Details
    • 2.14.2 GenSci Major Business
    • 2.14.3 GenSci Urotropin for Injection Product and Services
    • 2.14.4 GenSci Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 GenSci Recent Developments/Updates
  • 2.15 Teva
    • 2.15.1 Teva Details
    • 2.15.2 Teva Major Business
    • 2.15.3 Teva Urotropin for Injection Product and Services
    • 2.15.4 Teva Urotropin for Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Teva Recent Developments/Updates

3 Competitive Environment: Urotropin for Injection by Manufacturer

  • 3.1 Global Urotropin for Injection Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Urotropin for Injection Revenue by Manufacturer (2021-2026)
  • 3.3 Global Urotropin for Injection Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Urotropin for Injection by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Urotropin for Injection Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Urotropin for Injection Manufacturer Market Share in 2025
  • 3.5 Urotropin for Injection Market: Overall Company Footprint Analysis
    • 3.5.1 Urotropin for Injection Market: Region Footprint
    • 3.5.2 Urotropin for Injection Market: Company Product Type Footprint
    • 3.5.3 Urotropin for Injection Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Urotropin for Injection Market Size by Region
    • 4.1.1 Global Urotropin for Injection Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Urotropin for Injection Consumption Value by Region (2021-2032)
    • 4.1.3 Global Urotropin for Injection Average Price by Region (2021-2032)
  • 4.2 North America Urotropin for Injection Consumption Value (2021-2032)
  • 4.3 Europe Urotropin for Injection Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Urotropin for Injection Consumption Value (2021-2032)
  • 4.5 South America Urotropin for Injection Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Urotropin for Injection Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Urotropin for Injection Sales Quantity by Type (2021-2032)
  • 5.2 Global Urotropin for Injection Consumption Value by Type (2021-2032)
  • 5.3 Global Urotropin for Injection Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Urotropin for Injection Sales Quantity by Application (2021-2032)
  • 6.2 Global Urotropin for Injection Consumption Value by Application (2021-2032)
  • 6.3 Global Urotropin for Injection Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Urotropin for Injection Sales Quantity by Type (2021-2032)
  • 7.2 North America Urotropin for Injection Sales Quantity by Application (2021-2032)
  • 7.3 North America Urotropin for Injection Market Size by Country
    • 7.3.1 North America Urotropin for Injection Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Urotropin for Injection Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Urotropin for Injection Sales Quantity by Type (2021-2032)
  • 8.2 Europe Urotropin for Injection Sales Quantity by Application (2021-2032)
  • 8.3 Europe Urotropin for Injection Market Size by Country
    • 8.3.1 Europe Urotropin for Injection Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Urotropin for Injection Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Urotropin for Injection Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Urotropin for Injection Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Urotropin for Injection Market Size by Region
    • 9.3.1 Asia-Pacific Urotropin for Injection Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Urotropin for Injection Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Urotropin for Injection Sales Quantity by Type (2021-2032)
  • 10.2 South America Urotropin for Injection Sales Quantity by Application (2021-2032)
  • 10.3 South America Urotropin for Injection Market Size by Country
    • 10.3.1 South America Urotropin for Injection Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Urotropin for Injection Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Urotropin for Injection Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Urotropin for Injection Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Urotropin for Injection Market Size by Country
    • 11.3.1 Middle East & Africa Urotropin for Injection Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Urotropin for Injection Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Urotropin for Injection Market Drivers
  • 12.2 Urotropin for Injection Market Restraints
  • 12.3 Urotropin for Injection Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Urotropin for Injection and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Urotropin for Injection
  • 13.3 Urotropin for Injection Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Urotropin for Injection Typical Distributors
  • 14.3 Urotropin for Injection Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Urotropin for Injection market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Urogonadotropin for injection for female infertility caused by hypogonadotropic or normogonadotropic ovarian insufficiency
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global Urotropin for Injection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Urotropin for Injection market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Urotropin for Injection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Urotropin for Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Urotropin for Injection market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Urotropin for Injection
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Urotropin for Injection market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Yantai Dongcheng North Pharmaceutical, Maanshan Fengyuan Pharmaceutical, Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd., Ningbo Human Health Pharmaceutical Group, Livzon Group, Ningbo Human Health Pharmaceutical, Qingdao Kangyuan Pharmaceutical, Shanghai Tianwei Biopharmaceutical Co., Ltd., Ferring GmbH, IBSA Group, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Urotropin for Injection market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    75 Unit
    150 Unit
    Market segment by Application
    Hospital
    Clinic
    Major players covered
    Yantai Dongcheng North Pharmaceutical
    Maanshan Fengyuan Pharmaceutical
    Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd.
    Ningbo Human Health Pharmaceutical Group
    Livzon Group
    Ningbo Human Health Pharmaceutical
    Qingdao Kangyuan Pharmaceutical
    Shanghai Tianwei Biopharmaceutical Co., Ltd.
    Ferring GmbH
    IBSA Group
    Merck
    Livzon
    Gedeon Richter
    GenSci
    Teva
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Urotropin for Injection product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Urotropin for Injection, with price, sales quantity, revenue, and global market share of Urotropin for Injection from 2021 to 2026.
    Chapter 3, the Urotropin for Injection competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Urotropin for Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Urotropin for Injection market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Urotropin for Injection.
    Chapter 14 and 15, to describe Urotropin for Injection sales channel, distributors, customers, research findings and conclusion.

    Buy now